Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nardoguaianone L (also known as G-6) is a sesquiterpenoid natural product isolated from the roots and rhizomes of *Nardostachys jatamansi* DC., a plant traditionally used in Chinese medicine known as Gansong. It has been identified as a potential therapeutic agent for pancreatic cancer. Research indicates that nardoguaianone L inhibits the proliferation, colony formation, and migration of pancreatic cancer cells (such as the SW1990 line) and induces apoptosis. Its anti-tumor activity is primarily mediated through the regulation of the MET/PTEN/TGF-beta signaling pathway. Quantitative proteomics has shown that it modulates the expression of over 140 proteins involved in critical biological processes, including cell motility and survival, making it a candidate for further development in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nardoguaianone L.